Correspondence 0001493152-25-003731 from Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc.
Date: Jan. 27, 2025 · CIK: 0001533743 · Accession: 0001493152-25-003731
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283986
Letter
Re: Processa Pharmaceuticals, Inc.
January 27, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549
Attention: Mr. Christopher Edwards
Registration Statement on Form S-1
Registration No. 333-283986
Ladies and Gentlemen:
In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A.G.P./ALLIANCE GLOBAL PARTNERS, as Sole Placement Agent (the “Placement Agent”), hereby joins Processa Pharmaceuticals, Inc. (the “Company”) in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1, as amended (the “Registration Statement”), to become effective as of 4:30 p.m., Eastern Time, on January 27, 2025, or as soon thereafter as is practicable, or at such other time as the Company or its outside counsel, Foley & Lardner LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 of the General Rules and Regulations under the Act, the undersigned advises that copies of the Preliminary Prospectus, dated January 27, 2025, are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The Placement Agent is aware of its obligations under, and confirm that it is complying with, the provisions of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.
Very
truly yours,
A.G.P./ALLIANCE
GLOBAL PARTNERS
Show Raw Text
CORRESP
1
filename1.htm
January
27, 2025
VIA
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Mr. Christopher Edwards
Re:
Processa Pharmaceuticals, Inc.
Registration
Statement on Form S-1
Registration
No. 333-283986
Ladies
and Gentlemen:
In
accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”),
A.G.P./ALLIANCE GLOBAL PARTNERS, as Sole Placement Agent (the “Placement Agent”), hereby joins Processa Pharmaceuticals,
Inc. (the “Company”) in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration
Statement on Form S-1, as amended (the “Registration Statement”), to become effective as of 4:30 p.m., Eastern Time, on January
27, 2025, or as soon thereafter as is practicable, or at such other time as the Company or its outside counsel, Foley & Lardner LLP,
request by telephone that such Registration Statement be declared effective.
Pursuant
to Rule 460 of the General Rules and Regulations under the Act, the undersigned advises that copies of the Preliminary Prospectus, dated
January 27, 2025, are expected to be distributed to prospective dealers, institutional investors, retail investors and others as appears
to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The
Placement Agent is aware of its obligations under, and confirm that it is complying with, the provisions of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended, including the delivery requirement contained in such Rule.
Very
truly yours,
A.G.P./ALLIANCE
GLOBAL PARTNERS
By:
/s/
Thomas J. Higgins
Name:
Thomas J. Higgins
Title:
Managing Director